Nexsen Limited (ASX:NXN) reported a 30% rise in net loss to $6.55 million for FY26, driven by ongoing investment in its Group B Streptococcus rapid diagnostic and Asia-Pacific growth initiatives following its October 2025 IPO.
- 30% increase in net loss to $6.55 million
- IPO raised $8 million at 20 cents per share
- Clinical trials commenced for StrepSure GBS rapid sensor
- Secured HK$6 million Ignite grant and Hong Kong hospital partnership
- Leadership strengthened with key board and executive hires
Loss widens as Nexsen invests in clinical and commercial milestones
Nexsen Limited (ASX:NXN) reported a net loss after tax of $6.55 million for the financial year ended 30 June 2026, up 30% from $5.02 million in FY25. The widening loss reflects the company’s continued investment in its flagship Group B Streptococcus (GBS) rapid diagnostic sensor, StrepSure, and expansion efforts across the Asia-Pacific region following its $8 million IPO in October 2025.
Since listing, Nexsen has focused on executing its Prospectus strategy, which includes clinical development, regulatory preparation, and commercial partnerships. The company’s cash reserves stood at $4.49 million at year-end, a significant increase from $423,000 the prior year, bolstered by IPO proceeds and convertible note conversions.
Clinical trials and technology development progress
In line with its strategic roadmap, Nexsen commenced clinical trials for StrepSure in October 2025, aiming to enable real-time, point-of-care detection of GBS during labour. This rapid diagnostic tool targets improved antibiotic stewardship and neonatal outcomes by replacing traditional delayed laboratory testing.
During FY26, the company advanced assay performance, platform engineering, and manufacturing readiness for StrepSure while exploring additional biosensing applications, including infectious disease and biosecurity diagnostics. These developments align with the company’s goal to expand its portfolio beyond GBS into kidney function diagnostics and other areas of unmet clinical need.
Asia-Pacific expansion backed by grants and hospital partnerships
Nexsen secured its first Asia-Pacific regional grant and hospital partnership in FY26, key steps in its commercialisation pathway. The company was awarded an Ignite grant of approximately HK$6 million to support clinical validation and market entry activities for its biosensing platform in Hong Kong.
Complementing this, Nexsen signed a binding term sheet with GHK Hospital Limited, operator of Gleneagles Hospital Hong Kong, granting access to a 500-bed tertiary hospital and the wider IHH Healthcare network. This partnership provides a structured framework for hospital-based validation, real-world data collection, and commercial rollout across North Asia, reinforcing the company’s regional footprint.
Strengthening leadership to support growth and regulatory navigation
The company bolstered its leadership team with several key appointments during FY26. Professor Shekhar Kumta joined as a Non-Executive Director, bringing extensive clinical and regulatory expertise in point-of-care diagnostics. Richard Jarvis was appointed fractional Chief Financial Officer, adding public company finance and governance experience.
Additionally, Dr Kenneth Tsang, CEO of IHH Healthcare North Asia and Gleneagles Hospital Hong Kong, joined Nexsen’s Advisory Board, enhancing the company’s Asia-Pacific market access and hospital operations capabilities. These appointments aim to deepen Nexsen’s clinical translation, regulatory navigation, and capital management expertise.
Regulatory groundwork and future focus
Nexsen advanced preparatory work for regulatory engagement in key markets, including groundwork for FDA submissions and other regulatory interactions as part of its StrepSure and broader diagnostics portfolio roadmap. The company’s strengthened clinical data, regional hospital collaborations, and leadership team position it to better navigate regulatory pathways and payer discussions in the medium term.
Looking ahead, Nexsen remains focused on progressing StrepSure through clinical validation and regulatory submissions, converting hospital partnerships into commercial reference sites, and leveraging its biosensing platform into adjacent diagnostic markets. The company also emphasises disciplined capital management as it transitions from development to early commercialisation.
Financial position and governance
Nexsen ended FY26 with net assets of $5.66 million, a turnaround from a net liability position of $116,000 the previous year, largely due to capital raises and convertible note conversions. The company maintains a governance framework suitable for an early-stage medical technology firm, with compliance to ASX Listing Rules and continuous disclosure obligations.
No dividends were declared or paid during the year, consistent with the company’s development-stage status. The auditor issued an unmodified opinion on the financial statements, confirming compliance with accounting standards and regulatory requirements.
Bottom Line?
Nexsen’s FY26 results underline the costs of scaling a diagnostics startup but also highlight tangible progress in clinical trials, Asia-Pacific partnerships, and leadership depth as it prepares for regulatory submissions and early commercialisation.
Questions in the middle?
- Will Nexsen meet the performance milestones tied to its substantial share-based incentives within the next two years?
- How quickly can the Hong Kong hospital partnership translate into commercial sales or clinical adoption?
- What are the key regulatory hurdles remaining for StrepSure’s FDA and other market submissions?